

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**FOSUN PHARMA**

**复星医药**

**上海復星醫藥（集團）股份有限公司**

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02196)**

**(1) UNLOCKING OF THE FIRST TRANCHE OF RESTRICTED SHARES OF  
THE A SHARE FIRST GRANT UNDER THE 2022 RESTRICTED  
A SHARE INCENTIVE SCHEME**

**AND**

**(2) VESTING OF THE FIRST TRANCHE OF UNITS OF  
THE H SHARE FIRST GRANT UNDER THE 2022 H SHARE  
EMPLOYEE SHARE OWNERSHIP SCHEME**

References are made to the announcements of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**”) dated 29 August 2022, 1 December 2022, 14 December 2022, 3 September 2023, 22 September 2023 and 27 September 2023 and the circular of the Company dated 31 October 2022 (the “**Circular**”) in relation to, among other things, the adoption and implementation of the 2022 Restricted A Share Incentive Scheme and the 2022 H Share Employee Share Ownership Scheme. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Circular.

The 2022 Restricted A Share Incentive Scheme (including the Connected Grant) and the 2022 H Share Employee Share Ownership Scheme have been approved by the Shareholders at the EGM and/or the Class Meetings held on 29 November 2022, respectively.

On 9 January 2024, the Board considered and approved, among other things, the resolution in relation to the unlocking of the first tranche of the Restricted Shares of the A Share First Grant under the 2022 Restricted A Share Incentive Scheme. Under the relevant terms of the 2022 Restricted A Share Incentive Scheme, other than (1) 10 Participants who have retired or voluntarily resigned and the Restricted Shares granted to them but not unlocked have already been repurchased and cancelled, and (2) 3 Participants who have voluntarily resigned prior to the expiry date of the first Restriction Period (i.e. 12 December 2023, inclusive) and thus have not fulfilled the unlocking conditions in respect of all the Restricted Shares they held (which will separately be arranged to be repurchased and cancelled), the remaining 113 Participants of the A Share First Grant have fulfilled the unlocking conditions stipulated in the 2022 Restricted A Share Incentive Scheme of the first tranche in respect of the 774,114 Restricted Shares they hold. As a result, a total of 774,114 Restricted Shares can be unlocked.

On 9 January 2024, the Board also considered and approved, among other things, the resolution in relation to the vesting of the first tranche of the units of the H Share First Grant under the 2022 H Share Employee Share Ownership Scheme. Under the relevant terms of the 2022 H Share Employee Share Ownership Scheme, other than (1) 10 Holders who have retired or voluntarily resigned and the units granted to them but not vested have already been redeemed, and (2) 3 Holders who have voluntarily resigned prior to the commencement date of the first vesting period (i.e. 29 December 2023) and thus all the units they held have not been vested, the remaining 113 Holders of the H Share First Grant have fulfilled the vesting conditions stipulated in the 2022 H Share Employee Share Ownership Scheme of the first tranche in respect of the 16,556,200 units they hold. As a result, a total of 16,556,200 units can be vested.

By order of the Board  
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***  
**Wu Yifang**  
*Chairman*

Shanghai, the PRC

9 January 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.*

\* *For identification purposes only*